New Advances and Contemporary Management of Viral-Driven Head and Neck Cancer

The gaps in practice include the proper integration of new data with existing trials and practices in viral-driven head and neck cancers. There is also a lack of standardization and uniform adaptation of de-escalation trials, as well as barriers to the broader adaptation of these strategies in clinical practice.

There is a need for a deeper understanding of molecular profiling methods across different treatment stages and the application of personalized response monitoring and treatment adaptation based on recent trials.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe latest and ongoing trials of NPC and to foster evidence-based approaches in the treatment of locally advanced and metastatic NPC.
  • Describe methodologies for molecular profiling spanning pre-treatment, on-treatment, and post-treatment responses for NPC. Explore clinical trials focusing on personalized response monitoring and subsequent treatment adaptation.
  • Identify varying types and mechanisms of therapeutic HPV vaccines, as well as ongoing and future trials of viral therapeutic vaccines. Recognize optimal strategies for trial design and clinical implementation.
  • Summarize both completed and ongoing HPV de-escalation trials, identify barriers to adoption of de-escalation strategies, and synthesize practical considerations.

 

Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.50 Certificate of Attendance
    This activity was designated for 1.50 AMA PRA Category 1 Credit™.
Course opens: 
03/11/2024
Course expires: 
03/10/2026
Cost:
$0.00
Part of: 
2024 Multidisciplinary Head and Neck Cancers Symposium onDemand
Rating: 
0

C. Jillian Tsai, MD, PhD, MS, is employed by Princess Margaret Cancer Center and has no financial relationships with a commercial interest.

Lauren Shih, MD, is employed by the University of Washington and receives research compensation from Bayer Health Care and NIH.

Melvin Lee Kiang Chua, MBBS, PhD, is employed by the National Cancer Center and has no financial relationships with a commercial interest.

Eleni Rettig, MD, is employed by Brigham and Women's Hospital and receives research support from Naveris.

Daniel Ma, MD, is employed by the Mayo Clinic and he is a consultant with Current Health, EXACT Sciences and InSitu Biologics.

All relevant relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.50 Certificate of Attendance
    This activity was designated for 1.50 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.